AUPH - （Aurinia Pharmaceuticals Inc） AUPHのチャート
AUPHの企業情報
| symbol | AUPH |
|---|---|
| 会社名 | |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | ― |
| 概要 | 事業概要 -- Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. The Company’s head office is in Victoria, British Columbia, its U.S. commercial hub is in Rockville, Maryland, and the Company focuses its development efforts globally. |
| 本社所在地 | -- |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | ― |
| 設立年月日 | -- |
| 市場名 | -- |
| ipoyear | ―年 |
| 従業員数 | - |
| url | ― |
| nasdaq_url | https://www.nasdaq.com/symbol/auph |
| adr_tso | ― |
| EBITDA | EBITDA ー |
| 終値（lastsale） | 6.1601 |
| 時価総額（marketcap） | 525599241.0367 |
| 時価総額 | 時価総額 ― |
| 売上高 | 売上高 -- |
| 企業価値(EV) | 企業価値(EV) ー |
| 当期純利益 | 当期純利益 -- |
| 決算概要 | 決算概要 -- |
AUPHのテクニカル分析
AUPHのニュース
Aurinia Pharma reports promising topline data from renal biopsy sub─study of the AURORA trial 2023/04/06 13:02:47 EIN News Pharmaceuticals
Aurinia Pharmaceuticals Inc. announced promising results from … eGFR-based dosing protocol. Aurinia Pharmaceuticals is a fully integrated biopharmaceutical …
What''s Going On With Aurinia Pharmaceuticals Stock Wednesday? 2023/04/05 13:42:24 Benzinga
Aurinia Pharmaceuticals Inc (NASDAQ: AUPH ) shares are trading higher Wednesday after the company announced "promising results" from its AURORA Renal Biopsy Sub-Study . The Details: The study showed that the addition of the company''s oral medicine for the treatment of adult patients with active lupus nephritis, LUPKYNIS, on top of the current standard of care resulted in significantly earlier and greater reductions in proteinuria while maintaining … Full story available on Benzinga.com
Aurinia''s Lupkynis shows promise in 18-month kidney biopsy data 2023/04/05 11:07:11 Seeking Alpha
Aurinia Pharmaceuticals (AUPH) said biopsy data collected from AURORA program showed promising data for Lupkynis to treat lupus nephritis. Read more here
Aurinia Pharmaceuticals Announces Promising Topline Data from Renal Biopsy Sub-study of the AURORA Trial 2023/04/05 10:30:00 Business Wire
EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced promising results from the AURORA Renal Biopsy Sub-Study. LUPKYNIS is a novel agent approved for the treatment of adults with active lupus nephritis (LN). The addition of LUPKYNIS on top of the then current standard of care MMF and low-dose steroids in Aurinia’s Phase 3 AURORA 1 and AURORA 2 studies led to significantly earlier and greater reductions in proteinuria while main
Aurinia Pharma Stock: A Buyout Alone Will Unlock Value (AUPH) 2023/03/24 08:47:31 Seeking Alpha
My original investment thesis on Aurinia Pharma was that without a buyout, it has no future. Is that still the case? Click here for a full analysis of AUPH stock.
Aurinia Pharmaceuticals (AUPH) Investor Presentation - Slideshow 2023/03/07 18:58:56 Seeking Alpha
The following slide deck was published by Aurinia Pharmaceuticals Inc.
Morning Stocks in Queue: Hycroft Mining Holding Corporation (NASDAQ:HYMC -5.61%), Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH 1.47%) 2023/03/07 17:34:55 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Morning Stocks in Queue: Hycroft Mining Holding Corporation (NASDAQ:HYMC -5.61%), Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH 1.47%) appeared first on Stocks Equity .
Aurinia Pharmaceuticals''s Return On Capital Employed Insights 2023/03/03 14:49:18 Benzinga
Aurinia Pharmaceuticals (NASDAQ: AUPH ) brought in sales totaling $28.43 million during Q4 according to data provided by Benzinga Pro . However, earnings decreased 189.75%, resulting in a loss of $26.05 million. In Q3, Aurinia Pharmaceuticals brought in $55.78 million in sales but lost $8.99 million in earnings. What Is ROCE? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company … Full story available on Benzinga.com
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), Cinemark Holdings, Inc. (NYSE:CNK) – Shocking stocks 2023/03/01 13:26:22 Stock Equity
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH), Cinemark Holdings, Inc. (NYSE:CNK) – Shocking stocks appeared first on Stocks Equity .
Aurinia Pharmaceuticals Inc. (AUPH) Q4 2022 Earnings Call Transcript 2023/02/28 19:48:09 Seeking Alpha
Aurinia Pharmaceuticals Inc. (NASDAQ:NASDAQ:AUPH) Q4 2022 Earnings Conference Call February 28, 2023 8:30 AM ETCompany ParticipantsDana Lynch - Director of Corporate Communications &…
Investors’ Faith in Aurinia Pharmaceuticals Inc. (AUPH) could reap rewards if they hold on for the long haul 2022/12/29 18:00:00 US Post News
Currently, Aurinia Pharmaceuticals Inc.’s (AUPH) stock is trading at $4.35, marking a gain of 4.82% from last night’s close. At this price, the stock is -81.87% below its 52-week high of $24.00 and 6.88% above its 52-week low of $4.07. Based on the past 30-day period, the stock price is -16.51% below the high and […]
Is Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) A Suitable Stock For New Investors Today? 2022/12/29 15:30:00 Stocks Register
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) shares, rose in value on Wednesday, 12/28/22, with the stock price up by 0.97% to the previous day’s close as strong demand from buyers drove the stock to $4.15. Actively observing the price movement in the last trading, the stock closed the session at $4.11, falling within a range of $4.07 … Is Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) A Suitable Stock For New Investors Today? Read More »
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) Stock Forecast: By 2022, Bulls Expect $15.00 Per Share 2022/12/28 15:30:00 Marketing Sentinel
In the last trading session, 2.32 million shares of the Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) were traded, and its beta was 0.85. Most recently the company’s share price was $4.11, and it changed around -$0.42 or -9.27% from the last close, which brings the market valuation of the company to $595.62M. AUPH currently trades at a … Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) Stock Forecast: By 2022, Bulls Expect $15.00 Per Share Read More »
Investing in Aurinia Pharmaceuticals Inc. (AUPH) might be a great opportunity, but the stock is a bit undervalued 2022/12/16 15:16:00 US Post News
A share of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) closed at $4.53 per share on Thursday, down from $4.67 day before. While Aurinia Pharmaceuticals Inc. has underperformed by -3.00%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AUPH fell by -77.20%, with highs and lows ranging from $24.45 […]
Can you still get a good price for Aurinia Pharmaceuticals Inc. (AUPH) Shares at this point? 2022/12/08 12:00:00 US Post News
A share of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) closed at $4.65 per share on Wednesday, down from $4.78 day before. While Aurinia Pharmaceuticals Inc. has underperformed by -2.72%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AUPH fell by -76.99%, with highs and lows ranging from $24.45 […]